ADVERSE EVENTS IN THE TRIUMPH STUDY1

Adverse events occurring in >4% of patients taking TYVASO and more frequently than placebo in the pivotal trial (N=235)*†

Hero ImageHero Image
  • Of the 23 total discontinuations, 7 patients in the TYVASO group discontinued due to adverse events, compared to 4 in the placebo group1
  • In addition, adverse events occurring in ≥10% of patients were dizziness and diarrhea2

*Not a comprehensive list.
More than 3% greater than placebo.

IMPORTANT PATIENT CONSIDERATIONS

BEFORE PRESCRIBING TYVASO, YOU WILL NEED TO KNOW ALL OF YOUR PATIENT'S MEDICAL CONDITIONS, INCLUDING2:

  • Lung disease, such as asthma or chronic obstructive pulmonary disease (COPD)
  • Lung infection
  • Liver problems or kidney problems
  • Low blood pressure
  • Bleeding problems
  • Pregnancy or plans to become pregnant. It is not known if TYVASO will harm an unborn baby
  • Breastfeeding or plans to breastfeed. It is not known if TYVASO passes into breast milk. Talk to patients about the best way to feed a baby during treatment with TYVASO.

TYVASO and other medicines may affect each other, so know all of your patient’s prescription and non-prescription medicines, vitamins, and herbal supplements.

 

Make sure to ask patients if they take any of these medications2:

  • Anticoagulants
  • Diuretics
  • Antihypertensives or other drugs for heart disease
  • Gemfibrozil or other CYP2C8 inhibitors
  • Rifampin or other CYP2C8 inducers

It is not known if TYVASO is safe or effective in people under 18 years of age.